Physician profile
Anna Clair Sharp
NPI 1215618806
$1,180.72
in general payments reported to CMS, 2019-2025
16 companies · $774 in 2025
The $774 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.59 · 2024: $388 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.73 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $274.33 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $251.33 | 2025 | Fanapt |
| Harmony Biosciences LLC | $119.11 | 2025 | |
| Janssen Pharmaceuticals, INC | $91.31 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.24 | 2024-2025 | Caplyta |
| Lundbeck LLC | $61.54 | 2024-2025 | Rexulti, Abilify Maintena |
| Tris Pharma INC | $58.22 | 2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $44.55 | 2024-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $43.00 | 2025 | Rexulti |
| Neos Therapeutics, Lp | $35.76 | 2024 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $28.47 | 2025 | |
| Ironshore Pharmaceuticals INC. | $24.25 | 2024 | |
| Axsome Therapeutics, INC. | $22.45 | 2025 | Auvelity |
| Novo Nordisk INC | $20.32 | 2025 | |
| Collegium Pharmaceutical, INC. | $17.87 | 2025 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.97 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.